argenx
A Director at argenx leads the launch and commercialization of empasiprubart for Multifocal Motor Neuropathy (MMN), driving cross-functional execution to ensure market readiness for a transformative therapy.
Headquarters
Boston, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2008
Reaching Patients Through Immunology Innovation
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for argenx.
35% above the average for this role
OMG—argenx scores again with Vyvgart in ocular myasthenia gravis
2 weeks ago
Field Reimbursement Manager - Neurology (NY, NY)
Regeneron Pharmaceuticals
Senior Director, HCP Marketing (US)
Scholar Rock
Account Executive Sr. / TN
UCB
Associate Director, Marketing – Romvimza
Deciphera Pharmaceuticals
Neuromuscular Account Manager - Florida
BridgeBio Pharma
Director U S Hcp Marketing Strategy Hsct Tma Boston Massachusetts United States Of America
AstraZeneca